Jim Jenson work email
- Valid
- Valid
- Valid
- Valid
- Valid
Jim Jenson personal email
Jim Jenson phone numbers
James Jenson, PhD is a life-science entrepreneur and executive with over 35 years of experience in the pharmaceutical and biotechnology industries. He is currently the CEO of Morphoceuticals, Inc. Morphoceuticals is a Boston-based regenerative medicine company pioneering the use of A-I guided electroceuticals to reprogram endogenous non-neural cell networks with a focus on tissue repair and organ regeneration.
-
Ceo, DirectorMorphoceuticals, Inc. Nov 2023 - PresentMedford, Ma, UsMorphoceuticals Inc. is a new biotech creating the first map of the druggable bioelectrome. Using multiomics, bioelectric profiling and artificial intelligence (AI) we can exploit the electrical interface that exists throughout our bodies and controls tissue repair and organ regeneration. During development, the bioelectrome is a form of non-neural, multi-cellular cognition that knows what tissues to build and when to stop. By understanding and manipulating these bioelectric patterns, we can potentially rewrite them for the treatment of patients with many conditions that are currently inadequately addressed by existing therapeutic modalities. -
Strategic AdviserCytosite Biopharma Inc. Mar 2023 - Present
-
Founding Ceo, DirectorCytosite Biopharma Inc. 2016 - Apr 2023CytoSite Biopharma Inc. is a Boston-based biotechnology company developing a new technology to predict and monitor response to Immuno-Oncology (I-O) therapy. The company is developing a novel and proprietary small molecule PET imaging probe targeting the enzyme Granzyme B that will enable clinicians to predict early in the treatment cycle which patients will respond to I-O therapy, on a lesion by lesion basis.The technology upon which CytoSite is based was discovered by co-founders in the laboratory of Umar Mahmood MD PhD, Division Chief of Nuclear Medicine and Molecular Imaging (NMMI) at Massachusetts General Hospital, and Professor of Radiology, Harvard Medical School, together with colleagues Benjamin Larimer PhD, and Eric Wehrenberg-Klee MD.
-
Founding MemberBiopharma Executive Council, And The Biopharma Hub 2014 - 2023The BioPharma Hub is a peer group for Biopharma CEO’s to exchange advice and best practices in a confidential setting.
-
Founding Ceo, DirectorSabik Medical Inc. 2011 - 2016A biopharmaceutical company with a technology for the diagnosis, staging, and treatment of cancer, initially focused on prostate cancer, based on a platform technology known as Enzyme Mediated Imaging and Therapy (EMIT). EMIT technology enabled Sabik to design compounds that selectively deliver radioactively-labeled small molecule payloads to tumors by exploiting specific hydrolytic enzymes that are present in unusually high concentrations on the surface of certain tumor tissues. The technology was licensed from Harvard Medical School. -
Founding Ceo, Director, Sab MemberDicerna Pharmaceuticals, Inc. 2006 - 2014Lexington, Massachusetts, UsDicerna Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents based on its proprietary ‘GalXC' technology platform. These are second generation RNA interference (RNAi)-based therapies that engage the enzyme Dicer, which is an early step in the gene silencing process and a natural initiation point for the RNAi cascade. Dicerna is a clinical stage company with a growing pipeline of product candidates to address unmet medical needs in diseases involving the liver, including rare diseases, chronic liver diseases, and viral infectious diseases. Major alliances have been formed with multiple pharmaceutical companies.Named a FierceBiotech "10 next-gen biologics platforms to watch" (2012), and a "Fierce 15" company (2010).Dicerna completed its IPO in January 2014, with the highest opening-day gain of any company since 2005.Dicerna was acquired by Novo Nordisk in 2021 for $3.3 Billion.US FDA approval in October 2023 of Rivfloza, for children 9 or older and adults, for primary hyperoxaluria type 1 (PH1), developed using the proprietary GalXC RNAi technology platform.Co-founded with Douglas Fambrough, PhD of Oxford Bioscience Partners. The technology upon which Dicerna was founded is based on discoveries by co-founders John Rossi PhD, a Professor in the Division of Molecular Biology and Dean, Graduate School of Biological Sciences at City of Hope’s Beckman Research Institute, and Mark Behlke MD PHD, at Integrated DNA Technologies. -
Founding Ceo, DirectorZapaq, Inc./Comentis, Inc. 2001 - 2006South San Francisco, Ca, UsBuilt the company from the ground up to become a world-class competitor in its primary indication areas of Alzheimer's Disease and other neurological diseases. Key company achievement: design and development of an orally available, brain accessible inhibitor of the beta-secretase enzyme for use in Alzheimer's Disease therapy. A product was licensed to Astellas Pharma in one of the largest deals of its kind.The technology upon which Zapaq was based was discovered by co-founders Jordan Tang PhD, at the Oklahoma Medical Research Foundation, and Arun Ghosh at the University of Illinois at Chicago and Purdue University. -
Founding CeoPolaris Pharmaceuticals 1998 - 2000Company technology based on novel medicinal chemistry approaches to blocking protein-macromolecular interaction via multi-valent binding and covalent attachment of drugs. Technology sold by Founder to permit full-time launch of Zapaq.
-
Vp ResearchProcept 1992 - 1997Company was built to discover and develop inhibitors of T-cell antigen receptor and CD4. Financing was raised through a combination of venture capital, IPO February 1994, and research collaborations with Sandoz and Bristol Myers Squibb. The technology upon which Procept was formed was based on the work of Founder Ellis Reinherz MD of Harvard Medical School/Dana-Farber Cancer Institute
-
Director Protein Chemistry, Chairman SabTriton Biosciences/Berlex Biosciences/Schering Ag 1986 - 1992Protein chemistry support for the successful launch of ‘Betaseron’, a recombinant interferon approved for the treatment of Multiple Sclerosis, prescribed for over 25 years.R&D spokesperson for the sale of the company to Schering AG.
-
Research Investigator. Head, Molecular Immunology GroupHoffmann-Laroche 1983 - 1986
Jim Jenson Skills
Jim Jenson Education Details
-
Macalester CollegeBiology -
Cornell UniversityBiology/Biochemistry
Frequently Asked Questions about Jim Jenson
What company does Jim Jenson work for?
Jim Jenson works for Morphoceuticals, Inc.
What is Jim Jenson's role at the current company?
Jim Jenson's current role is Morphoceuticals, Inc..
What is Jim Jenson's email address?
Jim Jenson's email address is jj****@****ing.com
What is Jim Jenson's direct phone number?
Jim Jenson's direct phone number is +197846*****
What schools did Jim Jenson attend?
Jim Jenson attended Macalester College, Cornell University.
What are some of Jim Jenson's interests?
Jim Jenson has interest in Collecting Antiques, Exercise, Home Improvement, Reading, Gourmet Cooking, Sports, The Arts, Home Decoration, Cooking, Gardening.
What skills is Jim Jenson known for?
Jim Jenson has skills like Technology Transfer, Biochemistry, Molecular Biology, Lifesciences, Drug Discovery, Biotechnology, Drug Development, Protein Chemistry, Genomics, Cancer, Immunology, Pharmaceutical Industry.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial